Huadong Medicine: Announcement on the Implementation of Annual Equity Distribution in 2025
Securities code: 000963 Securities abbreviation: Huadong Medicine Announcement number: 2026-038
East China Pharmaceutical Co., Ltd.
2025 Annual Equity Distribution Implementation Announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
The 2025 annual equity distribution plan of East China Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or the "Company") has been reviewed and approved by the company's 2025 annual shareholders' meeting held on May 20, 2026. The equity distribution matters are now announced as follows:
1. The shareholders’ meeting reviewed and approved the profit distribution plan
The profit distribution plan reviewed and approved by the company's 2025 annual shareholders' meeting is as follows: Based on the company's existing total share capital of 1,753,736,848.00 shares, all shareholders will be distributed RMB 5.80 in cash (tax included) for every 10 shares. No bonus shares will be given, and no reserve funds will be converted into share capital. A total of 1,017,167,371.84 cash dividends will be distributed. yuan (including tax), and the remaining undistributed profits will be carried forward and distributed in subsequent years. If the company's total share capital changes before the implementation of this profit distribution plan, the distribution ratio per share will be adjusted based on the principle that the total distribution amount remains unchanged.
The total share capital of the company has not changed since the disclosure of the distribution plan to its implementation.
The distribution plan implemented this time is consistent with the distribution plan reviewed and approved by the company’s 2025 annual shareholders’ meeting.
The time before the implementation of the distribution plan was reviewed and approved by the shareholders’ meeting was less than two months.
2. Equity distribution plan
The company's annual equity distribution plan for 2025 is: based on the company's existing total share capital of 1,753,736,848 shares after excluding 0 shares that have been repurchased, all shareholders will be distributed RMB 5.80 in cash (including tax) for every 10 shares (tax included; after tax, investors in the Hong Kong market, overseas institutions (including QFII, RQFII) who hold shares through Shenzhen-Hong Kong Stock Connect, and individuals and securities investment funds holding pre-IPO restricted shares will be distributed for every 10 shares) 5.22 yuan; Dividend tax is levied at a differentiated rate for individuals holding post-IPO restricted shares, equity incentive restricted shares and unrestricted tradable shares. The company will not withhold personal income tax for the time being. When the individual transfers the stock, the tax payable will be calculated based on the holding period [Note]; the dividend tax involved in securities investment funds holding post-IPO restricted shares, equity incentive restricted shares and unrestricted tradable shares will be based on the portion of the fund shares held by Hong Kong investors. 10% levy, and a differentiated tax rate will be levied on the portion of fund shares held by mainland investors), no bonus shares will be given, and provident funds will not be converted into share capital.
[Note: According to the first-in, first-out principle, the holding period is calculated based on the investor's securities account. If the stock is held for less than 1 month (including 1 month), the back tax is 1.16 yuan per 10 shares; if the stock is held for more than 1 month to 1 year (including 1 year), the back tax is 0.58 yuan for every 10 shares; if the stock is held for more than 1 year, no back tax is required. 】
3. Equity registration date and ex-rights and ex-dividend date
The equity registration date for this equity distribution is: June 9, 2026, the ex-rights and ex-dividend date is: June 10, 2026, and the dividend payment date is: June 10, 2026.
4. Equity distribution objects
The objects of this distribution are: all shareholders of the company registered with China Securities Depository and Clearing Co., Ltd. Shenzhen Branch (hereinafter referred to as "China Securities Depository and Clearing Co., Ltd. Shenzhen Branch") as of the afternoon of June 9, 2026 after the Shenzhen Stock Exchange closes.
5. Equity distribution method
The cash dividends distributed by the Company to A-share shareholders entrusted by China Securities Clearing Company Shenzhen Branch will be directly transferred to their capital accounts through the shareholders’ custody securities company (or other custodian institution) on June 10, 2026.
The following cash dividends to A-share shareholders will be distributed by the Company itself:
Serial number Shareholder account number Shareholder name
1 08*****967 China Yuanda Group Co., Ltd.
2 08*****868 Hangzhou Huadong Pharmaceutical Group Co., Ltd.
During the application period for the equity distribution business (application date: May 22, 2026 to registration date: June 9, 2026), if the cash dividends entrusted to be distributed by China Securities Clearing Shenzhen Branch are insufficient due to the reduction of shares in the securities accounts of self-distributed shareholders, all legal responsibilities and consequences shall be borne by the company itself.
- If the investor transfers custody on the ex-dividend date, the dividends will be collected from the original custody securities firm.
6. Contact information
Consulting agency: Office of the Board of Directors of East China Pharmaceutical Co., Ltd.
Address: East China Medicine New Office Building, No. 858 Moganshan Road, Gongshu District, Hangzhou City, Zhejiang Province Contact: Hu Shufen
Postal code: 310011
Consultation hotline: 0571-89903300
Fax: 0571-89903366 (Please indicate "Equity Distribution Business" when faxing)
Email: [email protected]
7. Documents for reference
Documents issued by CSDC Shenzhen Branch confirming the specific time arrangements for equity distribution;
Resolution of the sixth meeting of the company’s eleventh board of directors;
The resolution of the company’s 2025 shareholders’ meeting;
Other documents required by Shenzhen Stock Exchange.
Board of Directors of East China Pharmaceutical Co., Ltd.
June 4, 2026